vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and AMPCO PITTSBURGH CORP (AP). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $104.4M, roughly 1.8× AMPCO PITTSBURGH CORP). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs -55.2%, a 68.6% gap on every dollar of revenue. On growth, AMPCO PITTSBURGH CORP posted the faster year-over-year revenue change (11.5% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $-64.0K). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -2.6%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Ampco-Pittsburgh Corporation is a specialty steel manufacturer headquartered in Downtown Pittsburgh, Pennsylvania. It is one of several companies to bear the Ampco name, and it should not be confused with the Milwaukee-based copper base alloy producer, Ampco Metal Inc.; the Miami-based cabinetry company; the Swiss aluminum corporation; or the Dallas-based tool company. Ampco was formed in 1929 and is a conglomerate made up of several previously established small steel makers. Five small compa...
AMPH vs AP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $104.4M |
| Net Profit | $24.4M | $-57.7M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | -54.0% |
| Net Margin | 13.3% | -55.2% |
| Revenue YoY | -1.8% | 11.5% |
| Net Profit YoY | -35.7% | -1958.9% |
| EPS (diluted) | $0.51 | $-2.87 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $104.4M | ||
| Q3 25 | $191.8M | $103.7M | ||
| Q2 25 | $174.4M | $108.9M | ||
| Q1 25 | $170.5M | $99.2M | ||
| Q4 24 | $186.5M | $93.6M | ||
| Q3 24 | $191.2M | $92.1M | ||
| Q2 24 | $182.4M | $107.1M | ||
| Q1 24 | $171.8M | $110.0M |
| Q4 25 | $24.4M | $-57.7M | ||
| Q3 25 | $17.4M | $-2.2M | ||
| Q2 25 | $31.0M | $-7.3M | ||
| Q1 25 | $25.3M | $1.1M | ||
| Q4 24 | $38.0M | $3.1M | ||
| Q3 24 | $40.4M | $-2.0M | ||
| Q2 24 | $37.9M | $2.0M | ||
| Q1 24 | $43.2M | $-2.7M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | -54.0% | ||
| Q3 25 | 13.2% | 1.1% | ||
| Q2 25 | 24.2% | -2.8% | ||
| Q1 25 | 21.9% | 3.9% | ||
| Q4 24 | 24.2% | 5.5% | ||
| Q3 24 | 29.8% | 2.0% | ||
| Q2 24 | 30.3% | 4.7% | ||
| Q1 24 | 27.9% | 0.1% |
| Q4 25 | 13.3% | -55.2% | ||
| Q3 25 | 9.0% | -2.1% | ||
| Q2 25 | 17.8% | -6.7% | ||
| Q1 25 | 14.8% | 1.2% | ||
| Q4 24 | 20.4% | 3.3% | ||
| Q3 24 | 21.1% | -2.1% | ||
| Q2 24 | 20.8% | 1.9% | ||
| Q1 24 | 25.1% | -2.5% |
| Q4 25 | $0.51 | $-2.87 | ||
| Q3 25 | $0.37 | $-0.11 | ||
| Q2 25 | $0.64 | $-0.36 | ||
| Q1 25 | $0.51 | $0.06 | ||
| Q4 24 | $0.74 | $0.16 | ||
| Q3 24 | $0.78 | $-0.10 | ||
| Q2 24 | $0.73 | $0.10 | ||
| Q1 24 | $0.81 | $-0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $10.7M |
| Total DebtLower is stronger | $608.7M | $117.9M |
| Stockholders' EquityBook value | $788.8M | $32.6M |
| Total Assets | $1.6B | $495.4M |
| Debt / EquityLower = less leverage | 0.77× | 3.61× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $10.7M | ||
| Q3 25 | $276.2M | $15.0M | ||
| Q2 25 | $231.8M | $9.9M | ||
| Q1 25 | $236.9M | $7.1M | ||
| Q4 24 | $221.6M | $15.4M | ||
| Q3 24 | $250.5M | $11.8M | ||
| Q2 24 | $217.8M | $7.9M | ||
| Q1 24 | $289.6M | $10.8M |
| Q4 25 | $608.7M | $117.9M | ||
| Q3 25 | $608.6M | $119.0M | ||
| Q2 25 | $607.7M | $115.9M | ||
| Q1 25 | $603.9M | $115.0M | ||
| Q4 24 | $601.6M | $116.4M | ||
| Q3 24 | $596.4M | $116.0M | ||
| Q2 24 | $586.9M | $119.4M | ||
| Q1 24 | $594.0M | $116.2M |
| Q4 25 | $788.8M | $32.6M | ||
| Q3 25 | $776.7M | $60.1M | ||
| Q2 25 | $757.5M | $62.7M | ||
| Q1 25 | $751.3M | $64.6M | ||
| Q4 24 | $732.3M | $58.9M | ||
| Q3 24 | $727.7M | $61.3M | ||
| Q2 24 | $713.3M | $58.0M | ||
| Q1 24 | $672.4M | $56.3M |
| Q4 25 | $1.6B | $495.4M | ||
| Q3 25 | $1.7B | $524.4M | ||
| Q2 25 | $1.6B | $537.2M | ||
| Q1 25 | $1.6B | $536.2M | ||
| Q4 24 | $1.6B | $530.9M | ||
| Q3 24 | $1.5B | $547.4M | ||
| Q2 24 | $1.5B | $560.8M | ||
| Q1 24 | $1.6B | $565.8M |
| Q4 25 | 0.77× | 3.61× | ||
| Q3 25 | 0.78× | 1.98× | ||
| Q2 25 | 0.80× | 1.85× | ||
| Q1 25 | 0.80× | 1.78× | ||
| Q4 24 | 0.82× | 1.98× | ||
| Q3 24 | 0.82× | 1.89× | ||
| Q2 24 | 0.82× | 2.06× | ||
| Q1 24 | 0.88× | 2.06× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $2.7M |
| Free Cash FlowOCF − Capex | $24.6M | $-64.0K |
| FCF MarginFCF / Revenue | 13.4% | -0.1% |
| Capex IntensityCapex / Revenue | 4.5% | 2.7% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $-8.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $2.7M | ||
| Q3 25 | $52.6M | $6.3M | ||
| Q2 25 | $35.6M | $-2.3M | ||
| Q1 25 | $35.1M | $-5.3M | ||
| Q4 24 | $29.0M | $7.5M | ||
| Q3 24 | $60.0M | $11.4M | ||
| Q2 24 | $69.1M | $-5.3M | ||
| Q1 24 | $55.3M | $4.5M |
| Q4 25 | $24.6M | $-64.0K | ||
| Q3 25 | $47.2M | $3.3M | ||
| Q2 25 | $25.0M | $-3.8M | ||
| Q1 25 | $24.4M | $-7.5M | ||
| Q4 24 | $16.6M | $3.7M | ||
| Q3 24 | $46.2M | $8.4M | ||
| Q2 24 | $63.1M | $-8.0M | ||
| Q1 24 | $46.5M | $1.7M |
| Q4 25 | 13.4% | -0.1% | ||
| Q3 25 | 24.6% | 3.2% | ||
| Q2 25 | 14.3% | -3.5% | ||
| Q1 25 | 14.3% | -7.5% | ||
| Q4 24 | 8.9% | 4.0% | ||
| Q3 24 | 24.1% | 9.1% | ||
| Q2 24 | 34.6% | -7.5% | ||
| Q1 24 | 27.1% | 1.5% |
| Q4 25 | 4.5% | 2.7% | ||
| Q3 25 | 2.8% | 2.9% | ||
| Q2 25 | 6.1% | 1.3% | ||
| Q1 25 | 6.3% | 2.2% | ||
| Q4 24 | 6.7% | 4.0% | ||
| Q3 24 | 7.2% | 3.2% | ||
| Q2 24 | 3.3% | 2.5% | ||
| Q1 24 | 5.1% | 2.6% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | -4.62× | ||
| Q4 24 | 0.76× | 2.40× | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | -2.64× | ||
| Q1 24 | 1.28× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
AP
| Forged And Cast Mill Rolls | $67.0M | 64% |
| Air Handling Systems | $14.3M | 14% |
| Heat Exchange Coils | $13.1M | 13% |
| Centrifugal Pumps | $10.3M | 10% |
| Forged Engineered Products | $4.0M | 4% |
